MedTrace Logo

Clinical Study for AL-CM

NCT04924998 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-01-31

No results posted yet for this study

Summary

In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.

Conditions

  • Immunoglobulin Light Amyloidosis Cardiomyopathy

Interventions

DRUG

current treatment of AL-CM

current treatment of AL-CM

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2031-06-01
Completion
2031-06-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04924998 on ClinicalTrials.gov